Product Name: B-raf Antibody
Species Reactivity: Human, Mouse, Rat
Tested Applications: ELISA, WB
Applications: B-raf antibody can be used for detection of B-raf by Western blot at 1 – 2 μg/mL.
User Note: Optimal dilutions for each application to be determined by the researcher.
Predicted Molecular Weight:
Immunogen: B-raf antibody was raised against an 18 amino acid synthetic peptide near the center of human B-raf.The immunogen is located within amino acids 330 – 380 of B-raf.
Host Species: Chicken
Purification: B-raf Antibody is affinity chromatography purified via peptide column.
Physical State: Liquid
CAS NO.: 35899-54-8
Product: SIBA
Buffer: B-raf Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration: 1 mg/mL
Storage Conditions: B-raf antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
Clonality: Polyclonal
Conjugate: Unconjugated
Alternate Names: B-raf Antibody: NS7, BRAF1, RAFB1, B-RAF1, Proto-oncogene B-Raf
Accession NO.: P15056
Protein Ino: 50403720
Official Symbol: BRAF
Geneid: 673
Background: B-raf Antibody: B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt pathways interact with each other to regulate growth and in some cases tumorigenesis. Mutations in B-raf have been associated with several cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung, leading to speculation on the possibility of B-raf as a therapeutic target for treating cancers. Mutations in this gene have also been associated with cardiofaciocutaneous syndrome (CFCS), a disease characterized by heart defects, mental retardation and a distinctive facial appearance.
PubMed ID:http://aac.asm.org/content/53/9/4002.abstract
